Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme for redox reactions, making it
central to energy metabolism. NAD+ is also an essential cofactor for non-redox NAD+ …

The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

NAD+ was discovered during yeast fermentation, and since its discovery, its important roles
in redox metabolism, aging, and longevity, the immune system and DNA repair have been …

Tumor extracellular matrix has been associated with drug resistance and immune
suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung …

Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …

Tumor cells constantly interact with their microenvironment, which comprises a variety of
immune cells together with endothelial cells and fibroblasts. The composition of the tumor …

Anticancer immunotherapies involving the use of immune-checkpoint inhibitors or adoptive
cellular transfer have emerged as new therapeutic pillars within oncology. These treatments …

Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …